Previous 10 | Next 10 |
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will present at the Jefferies 2019 ...
Kala Pharmaceuticals, Inc. (KALA) Q1 2019 Earnings Conference Call May 9, 2019 8:00 AM ET Company Participants Mary Reumuth – Chief Financial Officer Mark Iwicki – Chairman, President and Chief Executive Officer Todd Bazemore – Chief Operating Officer Kim B...
Kala Pharmaceuticals (NASDAQ: KALA ): Q1 GAAP EPS of -$0.75 in-line. More news on: Kala Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
–Conference Call and Webcast Today at 8:00 a.m. ET– Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug ...
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will present at the Bank of America...
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will report first quarter 2019 fina...
Gainers: ATAI +29.3% . MRTX +3.1% . KALA +3.1% . HPE +2.4% . PKD +2.1% . More news on: ATA Inc., Mirati Therapeutics, Inc., Kala Pharmaceuticals, Inc., Stocks on the move, Read more ...
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will present at the H.C. Wainwright...
Kala Pharmaceuticals, Inc. (KALA) Q4 2018 Earnings Conference Call March 11, 2019 4:30 p.m. ET Company Participants Mary Reumuth - CFO Mark Iwicki - Chairman, President, CEO Kim Brazzell - Chief Medical Officer Todd Bazemore - COO Hongming Chen - Chief Scientific Officer C...
Kala Pharmaceuticals (NASDAQ: KALA ): Q4 GAAP EPS of -$0.76 misses by $0.24. More news on: Kala Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Kala Pharmaceuticals Inc. Company Name:
KALA Stock Symbol:
NASDAQ Market:
Kala Pharmaceuticals Inc. Website:
2024-07-27 11:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 30.9% to $0.6 on volume of 558,931,853 shares NVIDIA Corporation (NVDA) fell 1.9% to $123.99 on volume of 249,243,816 shares Assure Holdings Corp. (IONM) rose 82.8% to $0.424 on vol...
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) is one of today's top gainers. The company's shares have moved 44.91% on the day to $6.55. Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus pe...